GLPG2737 single dose
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
Lakefront Biotherapeutics NV
Overview
GLPG2737 single dose is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
GLPG2737 single dose clinical trials
Explore related
Medical disclaimer. This page summarizes research about GLPG2737 single dose for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.